Cargando…
Impact of intravenous ferric carboxymaltose on heart failure with preserved and reduced ejection fraction
AIMS: Heart failure (HF) is a proinflammatory disease often associated with the onset of iron deficiency (ID). ID alters mitochondrial function, reducing the generation of cellular energy in skeletal muscle and cardiomyocytes. This study aimed to analyse the response of patients with HF to intraveno...
Autores principales: | , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8788053/ https://www.ncbi.nlm.nih.gov/pubmed/34964300 http://dx.doi.org/10.1002/ehf2.13753 |
_version_ | 1784639476934377472 |
---|---|
author | López‐Vilella, Raquel Lozano‐Edo, Silvia Arenas Martín, Patricia Jover‐Pastor, Pablo Ezzitouny, Meryem Sorolla Romero, José Calvo Asensio, María Martínez‐Solé, Julia Guerrero Cervera, Borja Sánchez Martínez, José Carlos Donoso Trenado, Víctor Sánchez‐Lázaro, Ignacio Martinez Dolz, Luis Almenar Bonet, Luis |
author_facet | López‐Vilella, Raquel Lozano‐Edo, Silvia Arenas Martín, Patricia Jover‐Pastor, Pablo Ezzitouny, Meryem Sorolla Romero, José Calvo Asensio, María Martínez‐Solé, Julia Guerrero Cervera, Borja Sánchez Martínez, José Carlos Donoso Trenado, Víctor Sánchez‐Lázaro, Ignacio Martinez Dolz, Luis Almenar Bonet, Luis |
author_sort | López‐Vilella, Raquel |
collection | PubMed |
description | AIMS: Heart failure (HF) is a proinflammatory disease often associated with the onset of iron deficiency (ID). ID alters mitochondrial function, reducing the generation of cellular energy in skeletal muscle and cardiomyocytes. This study aimed to analyse the response of patients with HF to intravenous iron administration according to the type of HF: preserved ejection fraction (HFpEF) or reduced ejection fraction (HFrEF). METHODS AND RESULTS: We conducted a retrospective, single‐centre study of 565 consecutive outpatients diagnosed with HF, recruited over 5 years, who were given intravenous ferric carboxymaltose (FCM) for the treatment of ID [defined as ferritin < 100 μg/L or ferritin 100–300 μg/L with transferrin saturation (TSAT) < 20%]. Clinical, laboratory, and echocardiographic parameters were analysed before and after administration. After FCM administration, overall ferritin, TSAT, and haemoglobin levels increased up to 5‐fold, 1.6‐fold, and 1.1‐fold, respectively, relative to baseline values in HF patients with reduced and preserved ejection fraction (P < 0.0001), with a greater increase in ferritin and TSAT in HFpEF patients. The left ventricular ejection fraction of the overall series improved by 8 percentage points in both types of HF (from 40% to 48%, P < 0.0001). The percentage of patients with normalization of right ventricular function increased by 6.9 points (from 74.1% to 81%) in HFpEF patients and by 6.4 points (from 53% to 59.4%) in the HFrEF subgroup (P < 0.0001). New York Heart Association functional status slightly improved, from a median of 2.4 (interquartile range, IQR: 2–2.7) to 1.9 (IQR: 1.5–2.5; P < 0.0001) after FCM in both types of HF. No changes were noted in plasma levels of liver enzymes, creatinine, or natriuretic peptide (P > 0.05). CONCLUSIONS: Intravenous iron administration appeared to improve ejection fraction and cardiac functional status in outpatients with ID and HF with both preserved and reduced ejection fraction. |
format | Online Article Text |
id | pubmed-8788053 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-87880532022-01-31 Impact of intravenous ferric carboxymaltose on heart failure with preserved and reduced ejection fraction López‐Vilella, Raquel Lozano‐Edo, Silvia Arenas Martín, Patricia Jover‐Pastor, Pablo Ezzitouny, Meryem Sorolla Romero, José Calvo Asensio, María Martínez‐Solé, Julia Guerrero Cervera, Borja Sánchez Martínez, José Carlos Donoso Trenado, Víctor Sánchez‐Lázaro, Ignacio Martinez Dolz, Luis Almenar Bonet, Luis ESC Heart Fail Original Articles AIMS: Heart failure (HF) is a proinflammatory disease often associated with the onset of iron deficiency (ID). ID alters mitochondrial function, reducing the generation of cellular energy in skeletal muscle and cardiomyocytes. This study aimed to analyse the response of patients with HF to intravenous iron administration according to the type of HF: preserved ejection fraction (HFpEF) or reduced ejection fraction (HFrEF). METHODS AND RESULTS: We conducted a retrospective, single‐centre study of 565 consecutive outpatients diagnosed with HF, recruited over 5 years, who were given intravenous ferric carboxymaltose (FCM) for the treatment of ID [defined as ferritin < 100 μg/L or ferritin 100–300 μg/L with transferrin saturation (TSAT) < 20%]. Clinical, laboratory, and echocardiographic parameters were analysed before and after administration. After FCM administration, overall ferritin, TSAT, and haemoglobin levels increased up to 5‐fold, 1.6‐fold, and 1.1‐fold, respectively, relative to baseline values in HF patients with reduced and preserved ejection fraction (P < 0.0001), with a greater increase in ferritin and TSAT in HFpEF patients. The left ventricular ejection fraction of the overall series improved by 8 percentage points in both types of HF (from 40% to 48%, P < 0.0001). The percentage of patients with normalization of right ventricular function increased by 6.9 points (from 74.1% to 81%) in HFpEF patients and by 6.4 points (from 53% to 59.4%) in the HFrEF subgroup (P < 0.0001). New York Heart Association functional status slightly improved, from a median of 2.4 (interquartile range, IQR: 2–2.7) to 1.9 (IQR: 1.5–2.5; P < 0.0001) after FCM in both types of HF. No changes were noted in plasma levels of liver enzymes, creatinine, or natriuretic peptide (P > 0.05). CONCLUSIONS: Intravenous iron administration appeared to improve ejection fraction and cardiac functional status in outpatients with ID and HF with both preserved and reduced ejection fraction. John Wiley and Sons Inc. 2021-12-28 /pmc/articles/PMC8788053/ /pubmed/34964300 http://dx.doi.org/10.1002/ehf2.13753 Text en © 2021 The Authors. ESC Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made. |
spellingShingle | Original Articles López‐Vilella, Raquel Lozano‐Edo, Silvia Arenas Martín, Patricia Jover‐Pastor, Pablo Ezzitouny, Meryem Sorolla Romero, José Calvo Asensio, María Martínez‐Solé, Julia Guerrero Cervera, Borja Sánchez Martínez, José Carlos Donoso Trenado, Víctor Sánchez‐Lázaro, Ignacio Martinez Dolz, Luis Almenar Bonet, Luis Impact of intravenous ferric carboxymaltose on heart failure with preserved and reduced ejection fraction |
title | Impact of intravenous ferric carboxymaltose on heart failure with preserved and reduced ejection fraction |
title_full | Impact of intravenous ferric carboxymaltose on heart failure with preserved and reduced ejection fraction |
title_fullStr | Impact of intravenous ferric carboxymaltose on heart failure with preserved and reduced ejection fraction |
title_full_unstemmed | Impact of intravenous ferric carboxymaltose on heart failure with preserved and reduced ejection fraction |
title_short | Impact of intravenous ferric carboxymaltose on heart failure with preserved and reduced ejection fraction |
title_sort | impact of intravenous ferric carboxymaltose on heart failure with preserved and reduced ejection fraction |
topic | Original Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8788053/ https://www.ncbi.nlm.nih.gov/pubmed/34964300 http://dx.doi.org/10.1002/ehf2.13753 |
work_keys_str_mv | AT lopezvilellaraquel impactofintravenousferriccarboxymaltoseonheartfailurewithpreservedandreducedejectionfraction AT lozanoedosilvia impactofintravenousferriccarboxymaltoseonheartfailurewithpreservedandreducedejectionfraction AT arenasmartinpatricia impactofintravenousferriccarboxymaltoseonheartfailurewithpreservedandreducedejectionfraction AT joverpastorpablo impactofintravenousferriccarboxymaltoseonheartfailurewithpreservedandreducedejectionfraction AT ezzitounymeryem impactofintravenousferriccarboxymaltoseonheartfailurewithpreservedandreducedejectionfraction AT sorollaromerojose impactofintravenousferriccarboxymaltoseonheartfailurewithpreservedandreducedejectionfraction AT calvoasensiomaria impactofintravenousferriccarboxymaltoseonheartfailurewithpreservedandreducedejectionfraction AT martinezsolejulia impactofintravenousferriccarboxymaltoseonheartfailurewithpreservedandreducedejectionfraction AT guerrerocerveraborja impactofintravenousferriccarboxymaltoseonheartfailurewithpreservedandreducedejectionfraction AT sanchezmartinezjosecarlos impactofintravenousferriccarboxymaltoseonheartfailurewithpreservedandreducedejectionfraction AT donosotrenadovictor impactofintravenousferriccarboxymaltoseonheartfailurewithpreservedandreducedejectionfraction AT sanchezlazaroignacio impactofintravenousferriccarboxymaltoseonheartfailurewithpreservedandreducedejectionfraction AT martinezdolzluis impactofintravenousferriccarboxymaltoseonheartfailurewithpreservedandreducedejectionfraction AT almenarbonetluis impactofintravenousferriccarboxymaltoseonheartfailurewithpreservedandreducedejectionfraction |